ReviewWorld journal of clinical cases2020
Role of monoclonal antibody drugs in the treatment of COVID-19.
Review in World journal of clinical cases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 46 citations in OpenAlex.
- Variation of the Neutrophil-to-Lymphocyte Ratio and Mean Platelet Volume in a Multicenter Study of Critically Ill Patients with COVID-19 Living at Different Altitudes.Medical sciences (Basel, Switzerland) · 2026Article
- Efficacy and safety of deflazacort in diabetic subjects infected with SARS-CoV-2.Multidisciplinary respiratory medicine · 2025Article
- Mucosal implications of oral Jak3-targeted drugs in COVID patients.Molecular medicine (Cambridge, Mass.) · 2025Review
- From Legacy to Innovation: Pidotimod's Expanding Therapeutic Horizon.Mediterranean journal of hematology and infectious diseases · 2025Review
- Evaluation of tonsillectomy in the treatment of SAPHO syndrome: past evidence and future directions.Frontiers in medicine · 2025Review
- Essential contribution of the JAK/STAT pathway to carcinogenesis, lytic infection of herpesviruses and pathogenesis of COVID‑19 (Review).Molecular medicine reports · 2024Review
- Antimicrobial resistance in intensive care patients hospitalized with SEPSIS: a comparison between the COVID-19 pandemic and pre-pandemic era.Frontiers in medicine · 2024Article
- Factors associated with disease severity of COVID‑19 in patients with type 2 diabetes mellitus.Biomedical reports · 2023Article
- Iron Dyshomeostasis in COVID-19: Biomarkers Reveal a Functional Link to 5-Lipoxygenase Activation.International journal of molecular sciences · 2022Article
- Molnupiravir as an Early Treatment for COVID-19: A Real Life Study.Pathogens (Basel, Switzerland) · 2022Article
- Fullerene Derivatives for Drug Delivery against COVID-19: A Molecular Dynamics Investigation of Dendro[60]fullerene as Nanocarrier of Molnupiravir.Nanomaterials (Basel, Switzerland) · 2022Article
- Post-infectious ST elevation myocardial infarction following a COVID-19 infection: A case report.Biomedical reports · 2022Article
- Improving BNT162b2 mRNA Vaccine Tolerability without Efficacy Loss by Pidotimod Supplementation.Mediterranean journal of hematology and infectious diseases · 2022Article
- Survey on COVID-19-related mortality associated with occupational infection during the first phase of the pandemic: A systematic review.Experimental and therapeutic medicine · 2022Article
- Advances in the development of therapeutic strategies against COVID-19 and perspectives in the drug design for emerging SARS-CoV-2 variants.Computational and structural biotechnology journal · 2022Review
- Immune response and potential therapeutic strategies for the SARS-CoV-2 associated with the COVID-19 pandemic.International journal of biological sciences · 2022Review
- New Insights in the Treatment of SAPHO Syndrome and Medication Recommendations.Journal of inflammation research · 2022Review
- Immunotherapy and CRISPR Cas Systems: Potential Cure of COVID-19?Drug design, development and therapy · 2022Review
- A Patent Review on the Therapeutic Application of Monoclonal Antibodies in COVID-19.International journal of molecular sciences · 2021Review
- Alterations in Circulating Monocytes Predict COVID-19 Severity and Include Chromatin Modifications Still Detectable Six Months after Recovery.Biomedicines · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Currently clinicians all around the world are experiencing a pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The clinical presentation of this pathology includes fever, dry cough, fatigue and acute respiratory distress syndrome that can lead to death infected patients. Current studies on coronavirus disease 2019 (COVID-19) continue to highlight the urgent need for an effective therapy. Numerous therapeutic strategies have been used until now but, to date, there is no specific effective treatment for SARS-CoV-2 infection. Elevated inflammatory cytokines have been reported in patients with COVID-19. Evidence suggests that elevated cytokine levels, reflecting a hyperinflammatory response secondary to SARS-CoV-2 infection, are responsible for multi-organ damage in patients with COVID-19. For these reason, numerous randomized clinical trials are currently underway to explore the effectiveness of biopharmaceutical drugs, such as, interleukin-1 blockers, interleukin-6 inhibitors, Janus kinase inhibitors, in COVID-19. The aim of the present paper is to briefly summarize the pathogenetic rationale and the state of the art of therapeutic strategy blocking hyperinflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.